一种缓释比马前列素眼用环的长期安全性和有效性 - Suppr

Suppr

超能文献

Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.

作者信息

Brandt James D, DuBiner Harvey B, Benza Robert, Sall Kenneth N, Walker Gary A, Semba Charles P

机构信息

University of California - Davis, Davis, California.

Clayton Eye Center, Morrow, Georgia.

出版信息

Ophthalmology. 2017 Oct;124(10):1565-1566. doi: 10.1016/j.ophtha.2017.04.022. Epub 2017 May 17.

DOI:10.1016/j.ophtha.2017.04.022

PMID:28528010

Abstract

摘要

相似文献

Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.一种缓释比马前列素眼用环的长期安全性和有效性

Ophthalmology. 2017 Oct;124(10):1565-1566. doi: 10.1016/j.ophtha.2017.04.022. Epub 2017 May 17.

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.0.01%比马前列素滴眼液与0.5%噻吗洛尔滴眼液对青光眼或高眼压症患者昼夜眼压、血压及灌注压的影响：一项随机、双盲、安慰剂对照临床试验

PLoS One. 2015 Oct 20;10(10):e0140601. doi: 10.1371/journal.pone.0140601. eCollection 2015.

Durysta - a bimatoprost implant for glaucoma.Durysta——一种用于治疗青光眼的比马前列素植入剂。

Med Lett Drugs Ther. 2020 Jul 27;62(1603):116-117.

Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.十二个月，随机对照试验，患者患有青光眼或高眼压症，使用贝美前列素 0.01%、0.0125% 和 0.03%。

Am J Ophthalmol. 2010 Apr;149(4):661-671.e1. doi: 10.1016/j.ajo.2009.12.003.

Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.用于青光眼治疗的比马前列素缓释植入剂：一项I/II期临床试验的6个月结果

Am J Ophthalmol. 2017 Mar;175:137-147. doi: 10.1016/j.ajo.2016.11.020. Epub 2016 Dec 22.

Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.比马前列素（卢美根）对高眼压症或青光眼患者的降眼压作用机制。

Ophthalmology. 2004 Sep;111(9):1658-62. doi: 10.1016/j.ophtha.2004.02.006.

Sustained drug delivery for glaucoma: current data and future trends.青光眼的持续药物递送：当前数据与未来趋势

Curr Opin Ophthalmol. 2017 Mar;28(2):169-174. doi: 10.1097/ICU.0000000000000334.

The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.比马前列素/噻吗洛尔固定复方制剂的安全性和有效性：在青光眼或高眼压症患者中与单一成分进行为期1年的双盲、随机平行对照研究。

J Glaucoma. 2010 Aug;19(6):424-6. doi: 10.1097/IJG.0b013e3181bdb586.

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.比马前列素降低青光眼和高眼压症患者眼压的长期疗效及安全性：第4年

Br J Ophthalmol. 2008 Oct;92(10):1387-92. doi: 10.1136/bjo.2007.128454. Epub 2008 Jul 11.

Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.0.03%比马前列素和0.004%曲伏前列素对青光眼或高眼压症患者的降眼压疗效。

Surv Ophthalmol. 2004 Mar;49 Suppl 1:S12-8. doi: 10.1016/j.survophthal.2003.12.015.

引用本文的文献

Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.用新兴疗法挑战青光眼：针对视力“隐形窃贼”的进展概述

Front Med (Lausanne). 2025 Mar 26;12:1527319. doi: 10.3389/fmed.2025.1527319. eCollection 2025.

Stem Cell-Based Therapies for Glaucoma Treatment: A Review Bridging the Gap in Veterinary Patients.基于干细胞的青光眼治疗方法：一篇弥合兽医患者差距的综述

Int J Mol Sci. 2024 Dec 30;26(1):232. doi: 10.3390/ijms26010232.

Drug Delivery Systems for Glaucoma: A Narrative Review.青光眼的药物递送系统：叙述性综述

Pharmaceuticals (Basel). 2024 Sep 2;17(9):1163. doi: 10.3390/ph17091163.

Advances and Challenges in Wearable Glaucoma Diagnostics and Therapeutics.可穿戴式青光眼诊断与治疗的进展与挑战

Bioengineering (Basel). 2024 Jan 30;11(2):138. doi: 10.3390/bioengineering11020138.

Therapeutic strategies for glaucoma and optic neuropathies.青光眼和视神经病变的治疗策略。

Mol Aspects Med. 2023 Dec;94:101219. doi: 10.1016/j.mam.2023.101219. Epub 2023 Oct 13.

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies.原发性开角型青光眼治疗中的技术进展：对当前纳米技术的见解

J Clin Med. 2023 Sep 6;12(18):5798. doi: 10.3390/jcm12185798.

Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.眼部给药系统的最新进展：眼用植入物在慢性眼病治疗中的突出地位。

Pharmaceutics. 2023 Jun 15;15(6):1746. doi: 10.3390/pharmaceutics15061746.

Adherence and Persistence to Medical Therapy in Glaucoma: An Overview.青光眼治疗的依从性和持续性：综述

Ophthalmol Ther. 2023 Oct;12(5):2227-2240. doi: 10.1007/s40123-023-00730-z. Epub 2023 Jun 14.

Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.眼部治疗的突破：用于眼前节疾病和青光眼的基于聚合物纳米的药物递送系统

Polymers (Basel). 2023 Mar 9;15(6):1373. doi: 10.3390/polym15061373.

Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress.用于治疗青光眼的眼内纳微尺度药物输送系统：设计策略和最新进展。

J Nanobiotechnology. 2023 Mar 10;21(1):84. doi: 10.1186/s12951-023-01838-x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验